Quantcast

Latest Eculizumab Stories

2014-06-23 08:27:32

CINCINNATI, June 23, 2014 /PRNewswire-USNewswire/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) and Cincinnati Children's Hospital Medical Center today announced the establishment of a collaboration and fund for the advancement of research in rare disease. Cincinnati Children's is a recognized center of excellence in pediatric rare diseases. Alexion is a global leader in the development and delivery of breakthrough therapies for patients with severe and life-threatening rare...

2014-06-03 23:05:30

On June 2, the FDA announced that certain lots of Soliris (eculizumab) Concentrated Solution for IV Infusion, by Alexion, are recalled due to visible particulates. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers. (PRWEB) June 03, 2014 AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on safety alerts for Soliris (eculizumab). The FDA...

2014-04-03 08:29:04

-- Phase 2 Clinical Trial Planned to Begin This Quarter -- SEATTLE, April 3, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that its Investigational New Drug Application (IND) to evaluate OMS721 for the inhibition of complement?mediated thrombotic microangiopathies (TMAs) has been cleared by the U.S. Food and Drug Administration (FDA). OMS721 is the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2),...

2014-03-10 08:29:22

- Phase 2 Clinical Trial in aHUS and Other TMAs Expected to Begin Next Quarter - SEATTLE, March 10, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data using OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 (MASP-2) program, in ex vivo studies of endothelial activation relevant to the pathophysiology of human atypical hemolytic uremic syndrome (aHUS), a form of thrombotic microangiopathy (TMA)....

2011-02-28 04:59:00

Canadian Association of PNH Patients raises the volume on plea for access to life-saving treatment To view the Social Media Release, click here: http://smr.newswire.ca/en/canadian-association-of-pnh-patients/patients-with-rare-blood-disease-turn-to-social-media TORONTO, Feb. 28 /PRNewswire/ - With so few people affected by rare diseases, how does a group of less than 90 patients across Canada make their voices heardon a life-and-death issue such as access to treatment? Barry...

2009-01-05 05:30:00

Alexion Licenses PDL's Queen et al. Patents for Soliris(R) INCLINE VILLAGE, Nev., and CHESHIRE, Conn., Jan. 5 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (Nasdaq: PDLI) and Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today jointly announced that the companies have entered into a definitive license agreement and settlement agreement that resolve the legal disputes between them relating to Alexion's humanized antibody, Soliris(R) (eculizumab) and PDL's patents known as the Queen et al....


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.